BRPI0515858A - anticorpos anti-il-12, epìtopos, composições, métodos e usos - Google Patents
anticorpos anti-il-12, epìtopos, composições, métodos e usosInfo
- Publication number
- BRPI0515858A BRPI0515858A BRPI0515858-3A BRPI0515858A BRPI0515858A BR PI0515858 A BRPI0515858 A BR PI0515858A BR PI0515858 A BRPI0515858 A BR PI0515858A BR PI0515858 A BRPI0515858 A BR PI0515858A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- antibodies
- epitopes
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
"ANTICORPOS ANTI-IL-12, EPìTOPOS, COMPOSIçõES, MéTODOS E USOS". Anticorpo anti-IL-12 que liga-se a uma porção da proteína de IL-12 correspondente a pelo menos um resíduo de aminoácido selecionado do grupo consistindo nos resíduos 15,17-21,23,40-43, 45-47, 54-56 e 58-62 da seqüencia de aminoácido da subunidade p40 da IL-12, incluindo os ácidos nucléicos isolados que codificam pelo menos um anticorpo anti-IL-12, vetores, células hospedeiras, animais transgênicos ou plantas, e métodos de preparação e emprego destes, tem aplicações em composições, métodos e dispositivos diagnósticos e/ou terapêuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63781904P | 2004-12-21 | 2004-12-21 | |
PCT/US2005/046063 WO2006069036A2 (en) | 2004-12-21 | 2005-12-20 | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515858A true BRPI0515858A (pt) | 2008-08-12 |
Family
ID=36602254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515858-3A BRPI0515858A (pt) | 2004-12-21 | 2005-12-20 | anticorpos anti-il-12, epìtopos, composições, métodos e usos |
Country Status (22)
Country | Link |
---|---|
US (8) | US8080247B2 (pt) |
EP (1) | EP1836294A4 (pt) |
JP (1) | JP2008523842A (pt) |
KR (1) | KR20070094927A (pt) |
CN (1) | CN101120087A (pt) |
AR (1) | AR051805A1 (pt) |
AU (1) | AU2005319278A1 (pt) |
BR (1) | BRPI0515858A (pt) |
CA (1) | CA2591813A1 (pt) |
CR (1) | CR9265A (pt) |
EA (1) | EA016022B1 (pt) |
IL (1) | IL183939A0 (pt) |
MY (1) | MY157915A (pt) |
NI (1) | NI200700155A (pt) |
NO (1) | NO20073778L (pt) |
NZ (2) | NZ555658A (pt) |
PE (1) | PE20061115A1 (pt) |
SG (1) | SG158150A1 (pt) |
TW (1) | TWI406943B (pt) |
UY (1) | UY29291A1 (pt) |
WO (1) | WO2006069036A2 (pt) |
ZA (1) | ZA200706036B (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6830751B1 (en) * | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US20120288494A1 (en) * | 1999-03-25 | 2012-11-15 | Abbott Laboratories | Anti-IL-12/IL-23 antibodies and uses thereof |
US7736650B2 (en) * | 2004-12-21 | 2010-06-15 | Centocor, Inc. | Anti-IL-12 antibody based vectors, host cells, and methods of production and uses |
EP1907421A4 (en) | 2005-06-30 | 2012-03-28 | Abbott Lab | IL-12 / P40 BINDING PROTEINS |
CA2621086A1 (en) | 2005-09-01 | 2007-03-08 | Schering Corporation | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
HUE027165T2 (en) * | 2006-10-02 | 2016-08-29 | Squibb & Sons Llc | Human antibodies that bind to CXCR4 and their uses |
EP2684895A1 (en) | 2006-10-27 | 2014-01-15 | AbbVie Biotechnology Ltd | Crystalline anti-hTNFalpha antibodies |
KR20150038227A (ko) | 2007-01-16 | 2015-04-08 | 애브비 인코포레이티드 | 건선의 치료방법 |
NZ598881A (en) | 2007-03-29 | 2013-11-29 | Abbvie Inc | Crystalline anti-human il-12 antibodies |
MX2010001488A (es) | 2007-08-08 | 2010-03-01 | Abbott Lab | Composiciones y metodos para cristalizar anticuerpos. |
EP2205276A4 (en) * | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
EP2215125A1 (en) | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
US8178092B2 (en) | 2008-03-18 | 2012-05-15 | Abbott Laboratories | Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23 |
CA2733642A1 (en) | 2008-08-14 | 2010-02-18 | Cephalon Australia Pty Ltd | Anti-il-12/il-23 antibodies |
RU2012114854A (ru) * | 2009-09-14 | 2013-10-27 | Эбботт Лэборетриз | Способы лечения псориаза |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
CN105572380A (zh) * | 2014-11-06 | 2016-05-11 | 上海市东方医院 | Il-12在诊断和治疗非小细胞肺癌远处转移中的应用 |
US11279754B2 (en) * | 2015-03-11 | 2022-03-22 | Rush University Medical Center | Compositions and methods for treating cancer |
JOP20170013B1 (ar) | 2016-01-22 | 2021-08-17 | Merck Sharp & Dohme | أجسام xi مضادة لعامل مضاد للتجلط |
KR102218714B1 (ko) | 2016-06-14 | 2021-02-24 | 머크 샤프 앤드 돔 코포레이션 | 항응고 인자 xi 항체 |
MX2019002252A (es) * | 2016-08-25 | 2019-07-04 | Japan Chem Res | Metodo para producir una proteina de fusion de anticuerpo. |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
CN109813897A (zh) * | 2017-11-18 | 2019-05-28 | 镇江亿特生物科技发展有限公司 | 盐酸可乐定快速时间分辨荧光免疫层析定量检测试纸条 |
JP7421500B2 (ja) | 2018-05-18 | 2024-01-24 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体でループスを治療する安全かつ有効な方法 |
US11253534B2 (en) | 2020-03-23 | 2022-02-22 | Sabine Hazan | Method of preventing COVID-19 infection |
US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
US11278520B2 (en) | 2020-03-31 | 2022-03-22 | Sabine Hazan | Method of preventing COVID-19 infection |
CN111549834B (zh) * | 2020-05-17 | 2021-08-10 | 福建金鼎建筑发展有限公司 | 一种基于地表水渗透的基坑开挖模型试验装置及使用方法 |
WO2023004282A2 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
CN114468015B (zh) * | 2022-03-15 | 2023-10-17 | 重庆大学 | 一种高肉粘性的胶原肠衣及其制备方法和用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0441900B1 (en) | 1988-11-10 | 1996-07-17 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5811523A (en) * | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
DE69034247T2 (de) | 1989-12-22 | 2008-04-17 | F. Hoffmann-La Roche Ag | Zytotoxischer Lymphozyten-Reifefaktor 40kD Untereinheit und monoklonale Antikörper spezifisch dafür |
US6683046B1 (en) * | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
DE4315127A1 (de) * | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
EP0804581B1 (en) | 1994-04-22 | 2001-09-26 | Corixa Corporation | Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
WO1998034635A1 (en) * | 1997-02-07 | 1998-08-13 | The Wistar Institute | Methods and compositions for the inhibition of interleukin-12 production |
US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
DE69935574T2 (de) * | 1998-01-23 | 2007-12-06 | F. Hoffmann-La Roche Ag | Antikörper gegen mensliches il-12 |
CN101066997B (zh) | 1999-03-25 | 2013-03-27 | 艾博特股份有限两合公司 | 结合人il-12的人抗体及其生产方法 |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
WO2001019373A2 (en) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US20030157105A1 (en) * | 2001-05-30 | 2003-08-21 | Carton Jill M. | Anti-p40 immunglobulin derived proteins, compositions, methods and uses |
WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
-
2005
- 2005-12-20 CN CNA2005800482713A patent/CN101120087A/zh active Pending
- 2005-12-20 BR BRPI0515858-3A patent/BRPI0515858A/pt not_active Application Discontinuation
- 2005-12-20 AU AU2005319278A patent/AU2005319278A1/en not_active Abandoned
- 2005-12-20 WO PCT/US2005/046063 patent/WO2006069036A2/en active Application Filing
- 2005-12-20 MY MYPI20056053A patent/MY157915A/en unknown
- 2005-12-20 AR ARP050105380A patent/AR051805A1/es unknown
- 2005-12-20 EP EP05854726A patent/EP1836294A4/en not_active Withdrawn
- 2005-12-20 KR KR1020077016698A patent/KR20070094927A/ko not_active Application Discontinuation
- 2005-12-20 TW TW094145355A patent/TWI406943B/zh active
- 2005-12-20 NZ NZ555658A patent/NZ555658A/en unknown
- 2005-12-20 US US11/722,312 patent/US8080247B2/en not_active Expired - Lifetime
- 2005-12-20 NZ NZ583153A patent/NZ583153A/en unknown
- 2005-12-20 CA CA002591813A patent/CA2591813A1/en not_active Abandoned
- 2005-12-20 JP JP2007548379A patent/JP2008523842A/ja active Pending
- 2005-12-20 SG SG200908473-2A patent/SG158150A1/en unknown
- 2005-12-20 EA EA200701363A patent/EA016022B1/ru unknown
- 2005-12-21 UY UY29291A patent/UY29291A1/es not_active Application Discontinuation
-
2006
- 2006-01-03 PE PE2006000036A patent/PE20061115A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183939A patent/IL183939A0/en unknown
- 2007-06-15 NI NI200700155A patent/NI200700155A/es unknown
- 2007-07-19 NO NO20073778A patent/NO20073778L/no not_active Application Discontinuation
- 2007-07-20 ZA ZA200706036A patent/ZA200706036B/xx unknown
- 2007-07-20 CR CR9265A patent/CR9265A/es not_active Application Discontinuation
-
2011
- 2011-11-18 US US13/299,831 patent/US8329170B2/en not_active Expired - Lifetime
-
2012
- 2012-11-06 US US13/669,894 patent/US8894990B2/en not_active Expired - Lifetime
-
2014
- 2014-10-13 US US14/512,757 patent/US9428579B2/en not_active Expired - Lifetime
-
2016
- 2016-07-22 US US15/217,099 patent/US9605067B2/en not_active Expired - Lifetime
-
2017
- 2017-02-14 US US15/432,636 patent/US9862766B2/en not_active Expired - Lifetime
- 2017-12-04 US US15/830,586 patent/US20180079809A1/en not_active Abandoned
-
2018
- 2018-12-04 US US16/209,326 patent/US20190085069A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515858A (pt) | anticorpos anti-il-12, epìtopos, composições, métodos e usos | |
AR051444A1 (es) | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos | |
CY1119650T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
EA200601603A1 (ru) | Миметические антитела glp-1 человека, композиции, способы и применения | |
CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
ECSP077888A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
EA200501524A1 (ru) | Антитела против амилоида, композиции, способы и применения | |
EA200970131A1 (ru) | Миметические антитела для glp-1 человека, композиции, способы и применения | |
WO2004101750A3 (en) | IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES | |
CR10181A (es) | Anticuerpos anti-il-23 humanos, composiciones, metodos y usos | |
BR0307216A (pt) | Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma) | |
BRPI0519775A2 (pt) | proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica | |
WO2003035847A3 (en) | Il-13 mutein proteins, antibodies, compositions, methods and uses | |
BR0214137A (pt) | Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos | |
BR0113112A (pt) | Anticorpos, de integrina antidual, composições, métodos e usos | |
AR037384A1 (es) | Anticuerpos anti-il-6, sus composiciones, metodos y usos | |
EA200702532A1 (ru) | Антитела против мср-1, композиции, способы и применения | |
RU2317998C2 (ru) | Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии | |
HRP20130022T1 (hr) | Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora | |
AR042968A1 (es) | Anticuerpos de virus anti-dengue composiciones metodos y usos | |
TH87431A (th) | แอนติบอดีชนิดแอนติ-il-12, เอพิโทป, สารผสม, วิธี และการใช้ | |
WO2008048871A3 (en) | Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses | |
DE60122721D1 (de) | Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers | |
BR9903530A (pt) | Protease aspártica ou peptìdeos derivados utilizados para imunização contra o carrapato | |
AR030133A1 (es) | Anticuerpos anti-tnf, composiciones, metodos y usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |